KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential. Issue 1 (10th September 2022)

• Record Type: Journal Article
• Authors: Crisman, Enrique; Duarte, Pablo; Dauden, Esteban; Cuadrado, Antonio; Rodríguez‐Franco, María Isabel; López, Manuela G.; León, Rafael
• Is Part Of: Medicinal research reviews. Volume 43:Issue 1(2023)
• Page Start: 237
• Page End: 287
• Publication Date: 2022-09-10
• Subjects: chronic diseases -- KEAP1‐NRF2 protein–protein interaction inhibitors -- NRF2 -- NRF2‐ARE pathway therapeutic potential -- phase II antioxidant response; Pharmacology -- Periodicals; Drugs -- Research -- Periodicals; 615
• DOI: 10.1002/med.21925
• Languages: English
• ISSNs: 0198-6325

Abstract

Abstract: The transcription factor nuclear factor erythroid 2‐related factor 2 (NRF2) is considered the master regulator of the phase II antioxidant response. It controls a plethora of cytoprotective genes related to oxidative stress, inflammation, and protein homeostasis, among other processes. Activation of these pathways has been described in numerous pathologies including cancer, cardiovascular, respiratory, renal, digestive, metabolic, autoimmune, and neurodegenerative diseases. Considering the increasing interest of discovering novel NRF2 activators due to its clinical application, initial efforts were devoted to the development of electrophilic drugs able to induce NRF2 nuclear accumulation by targeting its natural repressor protein Kelch‐like ECH‐associated protein 1 (KEAP1) through covalent modifications on cysteine residues. However, off‐target effects of these drugs prompted the development of an innovative strategy, the search of KEAP1‐NRF2 protein–protein interaction (PPI) inhibitors. These innovative activators are proposed to target NRF2 in a more selective way, leading to potentially improved drugs with the application for a variety of diseases that are currently under investigation. In this review, we summarize known KEAP1‐NRF2 PPI inhibitors to date and the bases of their design highlighting the most important features of their respective interactions. We also discuss the preclinical pharmacological properties described for the most promising compounds.